Our team
Board of Directors
Luis Sánchez-Lafuente
Chairman
Former Chief Executive Officer and co-owner of Laboratorios Gelos, SA. President of AB Biotics, SA
Carles Domènech
Executive chairman
Executive Chairman, CSO and co-Founder of Ability Pharmaceuticals, SL
José Manuel Valadés
General secretary
Lawyer, partner and founder of the law firm Alliant Abogados
Miquel Àngel Bonachera
Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in biochemistry and MBA.
BSc/MSc in biochemistry and MBA.
Sergi Audivert
Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in food technology and MBA.
BSc/MSc in food technology and MBA.
Sara Secall
Operating Partner & Life Sciences Investment Director of Inveready Asset Management
Santiago Descarrega
Venture Capital Partner at Fitalent (grup Everis)
LATEST NEWS
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
07.10.2022
Press Release
AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022
Press Release
Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022
Press Release
AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info